source
- Kailera says obesity pill succeeds in late-stage trial in ChinaThe drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.BioPharma Dive · 23d ago↗ source
- Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filingCompass Pathways said Tuesday that patients in the second of its two pivotal psilocybin trials maintained their response to treatment for at least six months, keeping the company on track to comple…Endpoints · 23d ago↗ source
- Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trialsThe GLP-1 pill being developed by Hengrui Pharma and Kailera Therapeutics posted decent results in two late-stage China-based trials — one in obesity and the other in diabetes. But the safety profi…